Hypoalbuminemia in Burn Patients (Halburns)
|ClinicalTrials.gov Identifier: NCT01436292|
Recruitment Status : Unknown
Verified September 2011 by Marc-Jacques Dubois, Centre hospitalier de l'Université de Montréal (CHUM).
Recruitment status was: Not yet recruiting
First Posted : September 19, 2011
Last Update Posted : September 19, 2011
|Condition or disease||Intervention/treatment||Phase|
|Second or Third Degree Burns||Drug: 5% human albumin solution (HAS)||Phase 4|
Each year approximately 2 million people are burned in the USA, from which 80,000 are hospitalized and 6,500 die. It is a well known fact that the two most important factors for mortality in burn patients are age and percent total body surface area burn (TBSA), which are unmodifiable findings.
A predictable inflammatory response takes place after a burn injury leading to profound changes in patient homeostasis. As a result, hypoalbuminemia is one of the common finding in severe burn patients. 21% of hospitalized adult patients are hypoalbuminemic on admission. After admission, worsening of existing hypoalbuminemia and development of de novo one are frequently seen.
Moreover, hypoalbuminemia, a potentially modifiable variable, has been strongly associated with poor clinical outcomes in critically ill patients and in burn patients.
Dynamic organ dysfunction scores have been introduced in critically ill patients few years ago in order to describe the evolution of patients on a daily basis. The Sequential Organ Failure Assessment (SOFA) score is now one of the most accepted score in critically ill patients and has been validated in general medico-surgical unit, as well as in trauma and cardiac surgery patients. It encompasses components assessing six organ functions. This score has also been shown to predict mortality in critically ill patients and in burn patients when used in a dynamic way.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||128 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Hypoalbuminemia in Burn Patients: Should we Care? - A Randomized Controlled Clinical Pilot Trial|
|Study Start Date :||September 2011|
|Estimated Primary Completion Date :||September 2015|
|Estimated Study Completion Date :||October 2015|
Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level
Drug: 5% human albumin solution (HAS)
Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:
≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; < 10 gr/L: 150 g of 5% HAS.
- Organ dysfunction as assessed by a change in the SOFA score from baseline to day 7 (or before if the patient is discharged from the ICU or died). [ Time Frame: Seven days ]
- ICU and hospital mortality [ Time Frame: 1, 3 and 6 months ]
- ICU and hospital length of stay [ Time Frame: 1, 3 and 6 months ]
- Free days of mechanical ventilation [ Time Frame: Seven days ]
- Caloric intake [ Time Frame: Seven days ]
- Fluid balance [ Time Frame: Seven days ]
- Incidence of infection [ Time Frame: Seven days ]
- Time to complete coverage defined as the time between admission and last surgery for grafting [ Time Frame: 1, 3 and 6 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01436292
|Contact: Roberto Eljaiek, MD||514 890-8000 ext email@example.com|
|Centre hospitalier de l'Université de Montréal (CHUM)||Not yet recruiting|
|Montréal, Quebec, Canada, H2W 1T8|
|Contact: Roberto Eljaiek, MD 514 890-8000 ext 15875 firstname.lastname@example.org|
|Contact: Marc-Jacques Dubois, MD - FRCPC 514 890-8000 ext 15875 email@example.com|
|Principal Investigator:||Roberto Eljaiek, MD||Université de Montréal - CHUM|
|Principal Investigator:||Marc-Jacques Dubois, MD - FRCPC||Université de Montréal - CHUM|